the company will increase its focus on the key therapeutic areas that meet unmet medical needs , provide the best opportunities for the business and deliver the greatest value for customers – diabetes , acute hospital care , vaccines and oncology . as part of its intensified portfolio assessment process , the company has divested a portion of its u.s. ophthalmics business and sold the u.s. marketing rights for saphris , 35 an antipsychotic indicated for the treatment of schizophrenia and bipolar i disorder in adults . the company 's portfolio assessment process is ongoing and future product divestitures may occur . in addition , in january 2014 , the company announced that it was evaluating the respective roles of merck 's animal health and consumer care businesses in the company 's strategy for long-term value creation . the company expects to complete the evaluation process and take action , if any , in 2014. the company could reach different decisions about the two businesses . the company 's re-focused research and development efforts include programs such as the company 's anti-pd-1 immunotherapy ( mk-3475 ) in oncology , which has received a breakthrough therapy designation from the u.s. food and drug administration ( the “ fda ” ) for advanced melanoma , merck 's bace inhibitor for alzheimer 's disease ( mk-8931 ) , the company 's all oral combination regimen for the treatment of chronic hepatitis c virus infection ( mk-5172/mk-8742 ) , and v503 , a nine-valent human papillomavirus ( “ hpv ” ) vaccine . in january 2014 , the company announced it has initiated the rolling submission of a biologics license application ( “ bla ” ) to the fda for mk-3475 in patients with advanced melanoma who have previously been treated with ipilimumab . during 2013 , the company received a breakthrough therapy designation for mk-5172/mk-8742 and has advanced the combination into phase 2b in a diverse range of chronic hepatitis c patients . the company has initiated phase 3 trials for its bace inhibitor ( mk-8931 ) and filed a bla with the fda for v503 . merck is pursuing emerging product opportunities independent of therapeutic area or modality and is building its biologics capabilities . the company expects to make externally sourced programs a greater component of its pipeline strategy . during 2013 , the company entered into a collaboration agreement for the development and commercialization of ertugliflozin , an investigational oral sodium glucose cotransporter ( “ sglt2 ” ) inhibitor being evaluated for the treatment of type 2 diabetes in phase 3 clinical development . the company is out-licensing or discontinuing selected late-stage clinical development assets and reducing its focus on platform technologies . during 2013 , the company out-licensed mk-1775 , an investigational treatment for certain types of ovarian cancer , and in january 2014 entered into an agreement to divest its sirna therapeutics , inc. subsidiary and related rnai technology assets . the company currently has several candidates under review with the fda : mk-5348 , vorapaxar , an investigational anti-thrombotic medicine ( also under review in the european union ( the “ eu ” ) ) ; v503 , a nine-valent hpv vaccine ; mk-8962 , corifollitropin alfa injection , an investigational fertility treatment ; mk-7243 , grastek , an investigational timothy grass pollen allergy immunotherapy tablet ( “ ait ” ) and mk-3641 , ragwitek , an investigational ragweed pollen ait . also , mk-8109 , vintafolide , an investigational cancer candidate , is under review in the eu and mk-7009 , vaniprevir , an investigational , oral twice-daily protease inhibitor for the treatment of chronic hepatitis c virus infection is under review in japan . in february 2014 , the company resubmitted its new drug application ( “ nda ” ) to the fda for mk-4305 , suvorexant , responding to the agency 's complete response letter ( “ crl ” ) received in 2013. in addition , the company anticipates resubmitting its nda application in 2014 to the fda for mk-8616 , sugammadex sodium injection , a medication for the reversal of certain muscle relaxants used during surgery for which the company received a crl in 2013 ( see “ research and development ” below ) . the company also has 12 candidates in phase 3 development and anticipates filing a new drug application ( “ nda ” ) or a bla , as applicable , with the fda with respect to several of these candidates in 2014 , including the completion of the rolling submission of the bla for mk-3475 for patients with advanced melanoma who have previously been treated with ipilimumab . in october 2013 , in connection with the implementation of company 's new global initiative , the company announced a global restructuring program ( the “ 2013 restructuring program ” ) . as part of the program , the company expects to reduce its total workforce by approximately 8,500 positions . these workforce reductions will primarily come from the elimination of positions in sales , administrative and headquarters organizations , as well as research and development . the company will also reduce its global real estate footprint and continue to improve the efficiency of its manufacturing and supply network . the company recorded total pretax costs of $ 1.2 billion in 2013 related to this restructuring program . the actions under the 2013 restructuring program are expected to be substantially completed by the end of 2015 with the cumulative pretax costs estimated to be approximately $ 2.5 billion to $ 3.0 billion . story_separator_special_tag one of these partnerships is the african comprehensive hiv/aids partnership in botswana , a collaboration with the government of botswana that was renewed in 2010 and supports botswana 's response to hiv/aids through a comprehensive and sustainable approach to hiv prevention , care , treatment , and support . privacy and data protection the company is subject to a number of privacy and data protection laws and regulations globally . the legislative and regulatory landscape for privacy and data protection continues to evolve . there has been increased attention to privacy and data protection issues in both developed and emerging markets with the potential to affect directly the company 's business , including recently enacted laws and regulations in the united states , europe , asia and latin america , and increased enforcement and litigation activity in the united states and other developed markets . operating results sales worldwide sales totaled $ 44.0 billion in 2013 , a decline of 7 % compared with $ 47.3 billion in 2012. the sales decline was driven primarily by lower sales of singulair . the patents that provided u.s. market exclusivity and market exclusivity in a number of major european markets for singulair expired in august 2012 and february 2013 , respectively , and the company experienced a significant and rapid decline in singulair sales in those markets thereafter . foreign exchange unfavorably affected global sales performance by 2 % in 2013. the revenue decline in 2013 also reflects lower sales of maxalt , cozaar and hyzaar , treatments for hypertension , temodar , clarinex , a non-sedating antihistamine , pegintron , a treatment for chronic hepatitis c , propecia , fosamax , a treatment for osteoporosis , and vytorin , a cholesterol modifying medicine . these declines were partially offset by growth in gardasil , a vaccine to help prevent certain diseases caused by four types of hpv , remicade and simponi , treatments for inflammatory diseases , janumet , a treatment for type 2 diabetes , isentress , a treatment for hiv-1 infection , dulera inhalation aerosol , a combination medicine for the treatment of asthma , and zostavax , a vaccine to help prevent shingles ( herpes zoster ) . sales in the united states were $ 18.2 billion in 2013 , a decline of 11 % compared with $ 20.4 billion in 2012. the sales decrease was driven primarily by lower sales of singulair , as well as maxalt , temodar , victrelis , an oral medicine for the treatment of chronic hepatitis c virus , and clarinex , partially offset by higher sales of gardasil , zetia , a cholesterol absorption inhibitor , and dulera inhalation aerosol . international sales were $ 25.8 billion in 2013 , a decline of 4 % compared with $ 26.9 billion in 2012. foreign exchange unfavorably affected international sales performance by 4 % in 2013. the decline was driven primarily by lower sales in the pharmaceutical segment , reflecting declines in japan , largely attributable to the unfavorable effect of foreign exchange , and europe that were partially offset by growth in the emerging markets . sales in japan declined 21 % in 2013 , to $ 3.9 billion , of which 17 % was due to the unfavorable effect of foreign exchange . the sales decline 40 reflects the ongoing impacts of the loss of the market exclusivity for several products , including cozaar and hyzaar , as well as lower sales of gardasil , reflecting the japanese government 's decision to suspend proactive recommendation of hpv vaccines , and declines in pegintron and rebetol , products for the treatment of chronic hepatitis c. these declines were partially offset by volume growth in januvia , a treatment for type 2 diabetes , nasonex , an inhaled nasal corticosteroid for the treatment of nasal allergy symptoms , zetia , and rotateq , a vaccine to help protect against rotavirus gastroenteritis in infants and children . sales in europe declined 1 % in 2013 , to $ 9.6 billion , including a 2 % favorable effect from foreign exchange driven by ongoing generic erosion and fiscal austerity measures in this region , partially offset by growth in remicade , simponi , janumet , januvia and isentress . sales in the emerging markets grew 3 % in 2013 , to $ 7.8 billion , including a 4 % unfavorable effect from foreign exchange reflecting higher sales of vaccine , hospital , hepatitis and immunology products , partially offset by lower sales of singulair and diversified brands . total international sales represented 59 % and 57 % of total sales in 2013 and 2012 , respectively . global efforts toward health care cost containment continue to exert pressure on product pricing and market access worldwide . in many international markets , government-mandated pricing actions have reduced prices of generic and patented drugs . in addition , other austerity measures negatively affected the company 's revenue performance in 2013. the company anticipates these pricing actions , including the biennial price reductions in japan , and other austerity measures will continue to negatively affect revenue performance in 2014. in october 2013 , the company sold its active pharmaceutical ingredient ( “ api ” ) manufacturing business and , effective december 31 , 2013 , certain related products within diversified brands . in november 2013 , merck sold the u.s. rights to certain ophthalmic products and in january 2014 sold the u.s. rights to saphris . the aggregate annual sales associated with these divested assets were approximately $ 625 million . the annual sales associated with the divested products were approximately $ 425 million of which approximately $ 385 million related to the pharmaceutical segment and $ 40 million related to the consumer care segment . the annual sales associated with the divested api manufacturing business were approximately $ 200 million and related to non-segment revenues . worldwide sales were $ 47.3 billion in 2012 , a decline

analysis of liquidity and capital resources merck 's strong financial profile enables it to fully fund research and development , focus on external alliances , support in-line products and maximize upcoming launches while providing significant cash returns to shareholders . replace_table_token_12_th cash provided by operating activities was $ 11.7 billion in 2013 , $ 10.0 billion in 2012 and $ 12.4 billion in 2011 . cash provided by operating activities in 2013 includes a payment made by the company of $ 480 million in connection with the previously disclosed settlement of the enhance litigation ( see note 10 to the consolidated financial statements ) . cash provided by operating activities in 2012 reflects higher contributions to its defined benefit plans as compared with 2013 and 2011. cash provided by operating activities in 2012 also includes a payment of $ 960 million related to the resolution of certain litigation related to vioxx . cash provided by operating activities in 2011 includes a $ 500 million payment made to j & j as a result of the arbitration settlement , as well as net payments of approximately $ 465 million to the internal revenue service as a result of the conclusion of its examination of certain of merck 's federal income tax returns . cash provided by operating activities continues to be the company 's primary source of funds to finance operating needs , capital expenditures , treasury stock purchases and dividends paid to shareholders . global economic conditions and ongoing sovereign debt issues , among other factors , have adversely affected foreign receivables in certain european countries ( see note 5 to the consolidated financial statements ) .


 Write a concise suspicious activity report of the following text delimited by triple backquotes. Return your response as a formal report which covers the key points highlighting the location,dates,entity names and account holder information in chronological order of the text.
     ```analysis of liquidity and capital resources merck 's strong financial profile enables it to fully fund research and development , focus on external alliances , support in-line products and maximize upcoming launches while providing significant cash returns to shareholders . replace_table_token_12_th cash provided by operating activities was $ 11.7 billion in 2013 , $ 10.0 billion in 2012 and $ 12.4 billion in 2011 . cash provided by operating activities in 2013 includes a payment made by the company of $ 480 million in connection with the previously disclosed settlement of the enhance litigation ( see note 10 to the consolidated financial statements ) . cash provided by operating activities in 2012 reflects higher contributions to its defined benefit plans as compared with 2013 and 2011. cash provided by operating activities in 2012 also includes a payment of $ 960 million related to the resolution of certain litigation related to vioxx . cash provided by operating activities in 2011 includes a $ 500 million payment made to j & j as a result of the arbitration settlement , as well as net payments of approximately $ 465 million to the internal revenue service as a result of the conclusion of its examination of certain of merck 's federal income tax returns . cash provided by operating activities continues to be the company 's primary source of funds to finance operating needs , capital expenditures , treasury stock purchases and dividends paid to shareholders . global economic conditions and ongoing sovereign debt issues , among other factors , have adversely affected foreign receivables in certain european countries ( see note 5 to the consolidated financial statements ) .
```    
 Suspicious Activity Report : the company will increase its focus on the key therapeutic areas that meet unmet medical needs , provide the best opportunities for the business and deliver the greatest value for customers – diabetes , acute hospital care , vaccines and oncology . as part of its intensified portfolio assessment process , the company has divested a portion of its u.s. ophthalmics business and sold the u.s. marketing rights for saphris , 35 an antipsychotic indicated for the treatment of schizophrenia and bipolar i disorder in adults . the company 's portfolio assessment process is ongoing and future product divestitures may occur . in addition , in january 2014 , the company announced that it was evaluating the respective roles of merck 's animal health and consumer care businesses in the company 's strategy for long-term value creation . the company expects to complete the evaluation process and take action , if any , in 2014. the company could reach different decisions about the two businesses . the company 's re-focused research and development efforts include programs such as the company 's anti-pd-1 immunotherapy ( mk-3475 ) in oncology , which has received a breakthrough therapy designation from the u.s. food and drug administration ( the “ fda ” ) for advanced melanoma , merck 's bace inhibitor for alzheimer 's disease ( mk-8931 ) , the company 's all oral combination regimen for the treatment of chronic hepatitis c virus infection ( mk-5172/mk-8742 ) , and v503 , a nine-valent human papillomavirus ( “ hpv ” ) vaccine . in january 2014 , the company announced it has initiated the rolling submission of a biologics license application ( “ bla ” ) to the fda for mk-3475 in patients with advanced melanoma who have previously been treated with ipilimumab . during 2013 , the company received a breakthrough therapy designation for mk-5172/mk-8742 and has advanced the combination into phase 2b in a diverse range of chronic hepatitis c patients . the company has initiated phase 3 trials for its bace inhibitor ( mk-8931 ) and filed a bla with the fda for v503 . merck is pursuing emerging product opportunities independent of therapeutic area or modality and is building its biologics capabilities . the company expects to make externally sourced programs a greater component of its pipeline strategy . during 2013 , the company entered into a collaboration agreement for the development and commercialization of ertugliflozin , an investigational oral sodium glucose cotransporter ( “ sglt2 ” ) inhibitor being evaluated for the treatment of type 2 diabetes in phase 3 clinical development . the company is out-licensing or discontinuing selected late-stage clinical development assets and reducing its focus on platform technologies . during 2013 , the company out-licensed mk-1775 , an investigational treatment for certain types of ovarian cancer , and in january 2014 entered into an agreement to divest its sirna therapeutics , inc. subsidiary and related rnai technology assets . the company currently has several candidates under review with the fda : mk-5348 , vorapaxar , an investigational anti-thrombotic medicine ( also under review in the european union ( the “ eu ” ) ) ; v503 , a nine-valent hpv vaccine ; mk-8962 , corifollitropin alfa injection , an investigational fertility treatment ; mk-7243 , grastek , an investigational timothy grass pollen allergy immunotherapy tablet ( “ ait ” ) and mk-3641 , ragwitek , an investigational ragweed pollen ait . also , mk-8109 , vintafolide , an investigational cancer candidate , is under review in the eu and mk-7009 , vaniprevir , an investigational , oral twice-daily protease inhibitor for the treatment of chronic hepatitis c virus infection is under review in japan . in february 2014 , the company resubmitted its new drug application ( “ nda ” ) to the fda for mk-4305 , suvorexant , responding to the agency 's complete response letter ( “ crl ” ) received in 2013. in addition , the company anticipates resubmitting its nda application in 2014 to the fda for mk-8616 , sugammadex sodium injection , a medication for the reversal of certain muscle relaxants used during surgery for which the company received a crl in 2013 ( see “ research and development ” below ) . the company also has 12 candidates in phase 3 development and anticipates filing a new drug application ( “ nda ” ) or a bla , as applicable , with the fda with respect to several of these candidates in 2014 , including the completion of the rolling submission of the bla for mk-3475 for patients with advanced melanoma who have previously been treated with ipilimumab . in october 2013 , in connection with the implementation of company 's new global initiative , the company announced a global restructuring program ( the “ 2013 restructuring program ” ) . as part of the program , the company expects to reduce its total workforce by approximately 8,500 positions . these workforce reductions will primarily come from the elimination of positions in sales , administrative and headquarters organizations , as well as research and development . the company will also reduce its global real estate footprint and continue to improve the efficiency of its manufacturing and supply network . the company recorded total pretax costs of $ 1.2 billion in 2013 related to this restructuring program . the actions under the 2013 restructuring program are expected to be substantially completed by the end of 2015 with the cumulative pretax costs estimated to be approximately $ 2.5 billion to $ 3.0 billion . story_separator_special_tag one of these partnerships is the african comprehensive hiv/aids partnership in botswana , a collaboration with the government of botswana that was renewed in 2010 and supports botswana 's response to hiv/aids through a comprehensive and sustainable approach to hiv prevention , care , treatment , and support . privacy and data protection the company is subject to a number of privacy and data protection laws and regulations globally . the legislative and regulatory landscape for privacy and data protection continues to evolve . there has been increased attention to privacy and data protection issues in both developed and emerging markets with the potential to affect directly the company 's business , including recently enacted laws and regulations in the united states , europe , asia and latin america , and increased enforcement and litigation activity in the united states and other developed markets . operating results sales worldwide sales totaled $ 44.0 billion in 2013 , a decline of 7 % compared with $ 47.3 billion in 2012. the sales decline was driven primarily by lower sales of singulair . the patents that provided u.s. market exclusivity and market exclusivity in a number of major european markets for singulair expired in august 2012 and february 2013 , respectively , and the company experienced a significant and rapid decline in singulair sales in those markets thereafter . foreign exchange unfavorably affected global sales performance by 2 % in 2013. the revenue decline in 2013 also reflects lower sales of maxalt , cozaar and hyzaar , treatments for hypertension , temodar , clarinex , a non-sedating antihistamine , pegintron , a treatment for chronic hepatitis c , propecia , fosamax , a treatment for osteoporosis , and vytorin , a cholesterol modifying medicine . these declines were partially offset by growth in gardasil , a vaccine to help prevent certain diseases caused by four types of hpv , remicade and simponi , treatments for inflammatory diseases , janumet , a treatment for type 2 diabetes , isentress , a treatment for hiv-1 infection , dulera inhalation aerosol , a combination medicine for the treatment of asthma , and zostavax , a vaccine to help prevent shingles ( herpes zoster ) . sales in the united states were $ 18.2 billion in 2013 , a decline of 11 % compared with $ 20.4 billion in 2012. the sales decrease was driven primarily by lower sales of singulair , as well as maxalt , temodar , victrelis , an oral medicine for the treatment of chronic hepatitis c virus , and clarinex , partially offset by higher sales of gardasil , zetia , a cholesterol absorption inhibitor , and dulera inhalation aerosol . international sales were $ 25.8 billion in 2013 , a decline of 4 % compared with $ 26.9 billion in 2012. foreign exchange unfavorably affected international sales performance by 4 % in 2013. the decline was driven primarily by lower sales in the pharmaceutical segment , reflecting declines in japan , largely attributable to the unfavorable effect of foreign exchange , and europe that were partially offset by growth in the emerging markets . sales in japan declined 21 % in 2013 , to $ 3.9 billion , of which 17 % was due to the unfavorable effect of foreign exchange . the sales decline 40 reflects the ongoing impacts of the loss of the market exclusivity for several products , including cozaar and hyzaar , as well as lower sales of gardasil , reflecting the japanese government 's decision to suspend proactive recommendation of hpv vaccines , and declines in pegintron and rebetol , products for the treatment of chronic hepatitis c. these declines were partially offset by volume growth in januvia , a treatment for type 2 diabetes , nasonex , an inhaled nasal corticosteroid for the treatment of nasal allergy symptoms , zetia , and rotateq , a vaccine to help protect against rotavirus gastroenteritis in infants and children . sales in europe declined 1 % in 2013 , to $ 9.6 billion , including a 2 % favorable effect from foreign exchange driven by ongoing generic erosion and fiscal austerity measures in this region , partially offset by growth in remicade , simponi , janumet , januvia and isentress . sales in the emerging markets grew 3 % in 2013 , to $ 7.8 billion , including a 4 % unfavorable effect from foreign exchange reflecting higher sales of vaccine , hospital , hepatitis and immunology products , partially offset by lower sales of singulair and diversified brands . total international sales represented 59 % and 57 % of total sales in 2013 and 2012 , respectively . global efforts toward health care cost containment continue to exert pressure on product pricing and market access worldwide . in many international markets , government-mandated pricing actions have reduced prices of generic and patented drugs . in addition , other austerity measures negatively affected the company 's revenue performance in 2013. the company anticipates these pricing actions , including the biennial price reductions in japan , and other austerity measures will continue to negatively affect revenue performance in 2014. in october 2013 , the company sold its active pharmaceutical ingredient ( “ api ” ) manufacturing business and , effective december 31 , 2013 , certain related products within diversified brands . in november 2013 , merck sold the u.s. rights to certain ophthalmic products and in january 2014 sold the u.s. rights to saphris . the aggregate annual sales associated with these divested assets were approximately $ 625 million . the annual sales associated with the divested products were approximately $ 425 million of which approximately $ 385 million related to the pharmaceutical segment and $ 40 million related to the consumer care segment . the annual sales associated with the divested api manufacturing business were approximately $ 200 million and related to non-segment revenues . worldwide sales were $ 47.3 billion in 2012 , a decline

